Welcome to our dedicated page for BridgeBio Oncology Therapeutics SEC filings (Ticker: BBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
Registration of 63,054,549 shares of Common Stock by the Selling Securityholders. This Prospectus Supplement No. 7 to the Prospectus (Registration No. 333-289940) registers 63,054,549 shares of common stock for resale by selling holders and attaches the Company’s Form 10-Q for the quarterly period ended March 31, 2026.
The supplement updates the Prospectus and should be read with it. The attached Form 10-Q reports a net loss of $42.1 million for the three months ended March 31, 2026 and cash, cash equivalents, and marketable securities of approximately $388.9 million as of March 31, 2026. Shares outstanding were 80,107,104 as of May 7, 2026.
BridgeBio Oncology Therapeutics, Inc. reported a net loss of $42.1M for the three months ended March 31, 2026, compared with $22.1M a year earlier, as research and development spending nearly doubled.
R&D expenses rose to $39.8M from $20.6M, while general and administrative costs increased to $6.4M. The company used $35.9M in operating cash during the quarter and ended with $388.9M in cash, cash equivalents, and marketable securities.
Management states this liquidity should fund operations for at least one year from the financial statement issuance date, but the company expects continued losses and anticipates needing additional capital to advance its oncology pipeline and potential commercialization efforts.
BridgeBio Oncology Therapeutics, Inc. reported a net loss of $42.1M for the three months ended March 31, 2026, compared with $22.1M a year earlier, as research and development spending nearly doubled.
R&D expenses rose to $39.8M from $20.6M, while general and administrative costs increased to $6.4M. The company used $35.9M in operating cash during the quarter and ended with $388.9M in cash, cash equivalents, and marketable securities.
Management states this liquidity should fund operations for at least one year from the financial statement issuance date, but the company expects continued losses and anticipates needing additional capital to advance its oncology pipeline and potential commercialization efforts.
BridgeBio Oncology Therapeutics reported a wider net loss for the first quarter of 2026 while advancing its three RAS‑pathway cancer programs. Net loss was $42.1 million for the quarter ended March 31, 2026, compared with $22.1 million a year earlier, driven mainly by higher research and development spending as multiple clinical trials progressed.
R&D expenses rose to $39.8 million from $20.6 million, and general and administrative costs increased to $6.4 million from $2.5 million, reflecting standalone operations after its de‑SPAC transaction. The company held $388.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 and expects this to fund operations into 2028. BBOT highlighted encouraging early efficacy and safety signals from BBO‑8520, BBO‑11818 and BBO‑10203, with updated clinical data across all three programs expected in the second half of 2026.
BridgeBio Oncology Therapeutics reported a wider net loss for the first quarter of 2026 while advancing its three RAS‑pathway cancer programs. Net loss was $42.1 million for the quarter ended March 31, 2026, compared with $22.1 million a year earlier, driven mainly by higher research and development spending as multiple clinical trials progressed.
R&D expenses rose to $39.8 million from $20.6 million, and general and administrative costs increased to $6.4 million from $2.5 million, reflecting standalone operations after its de‑SPAC transaction. The company held $388.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 and expects this to fund operations into 2028. BBOT highlighted encouraging early efficacy and safety signals from BBO‑8520, BBO‑11818 and BBO‑10203, with updated clinical data across all three programs expected in the second half of 2026.
BridgeBio Oncology Therapeutics COO and Principal Financial Officer Elmelech Idan received a grant of stock options for 758,222 shares of Common Stock. The options have an exercise price of 7.6600 per share and expire on May 9, 2036. Vesting occurs in 48 substantially equal monthly installments beginning on April 20, 2026, contingent on continued service.
BridgeBio Oncology Therapeutics COO and Principal Financial Officer Elmelech Idan received a grant of stock options for 758,222 shares of Common Stock. The options have an exercise price of 7.6600 per share and expire on May 9, 2036. Vesting occurs in 48 substantially equal monthly installments beginning on April 20, 2026, contingent on continued service.
BridgeBio Oncology Therapeutics reported that President and CEO Pedro Beltran received a grant of stock options covering 1,103,837 shares of common stock. The options have an exercise price of $7.66 per share and were awarded at no cost to him.
These options expire on May 9, 2036 and vest in substantially equal monthly installments, with 1/48 of the total vesting on each monthly anniversary of April 20, 2026, contingent on his continued service. Following this grant, he holds options for 1,103,837 shares directly.
BridgeBio Oncology Therapeutics reported that President and CEO Pedro Beltran received a grant of stock options covering 1,103,837 shares of common stock. The options have an exercise price of $7.66 per share and were awarded at no cost to him.
These options expire on May 9, 2036 and vest in substantially equal monthly installments, with 1/48 of the total vesting on each monthly anniversary of April 20, 2026, contingent on his continued service. Following this grant, he holds options for 1,103,837 shares directly.
BridgeBio Oncology Therapeutics, Inc. is registering 63,054,549 shares of Common Stock for resale by named selling securityholders under a shelf prospectus.
The prospectus states the company will not receive proceeds from these resales except for cash received upon exercise of 1,907,207 Options. The registration satisfies contractual registration rights and permits sales in varied methods and prices.
BridgeBio Oncology Therapeutics, Inc. Chief Med & Dev Officer Ben Yong reported a routine tax-related share disposition. On April 1, 2026, 1,047 shares of Common Stock were withheld by the company at $9.03 per share to cover his tax obligations upon vesting of restricted stock units. After this withholding, Yong directly holds 45,623 shares of the company’s Common Stock, indicating he retains the vast majority of his equity position and that the transaction was not an open-market sale.
BridgeBio Oncology Therapeutics, Inc. President and CEO Pedro Beltran had 1,047 shares of Common Stock withheld at $9.03 per share to cover tax obligations from the vesting of restricted stock units.
After this tax-withholding disposition, he directly holds 45,623 shares of the company’s Common Stock. This is a routine, non–open-market event tied to equity compensation rather than an active sale in the market.
BridgeBio Oncology Therapeutics, Inc. former officer Uneek Mehra reported a small share disposition tied to taxes, not an open-market trade. On the vesting of restricted stock units, the company withheld 524 shares of Common Stock at $9.03 per share to cover tax withholding obligations. After this tax-withholding transaction, Mehra directly holds 22,806 shares of BridgeBio Oncology common stock.